Retina4Future - COST Action CA24105

Short Bio: As the Chief Operating Officer at Miramoon Pharma, I bring over two decades of experience spanning developmental neuroscience, regenerative therapies, and the pharmaceutical industry. Since transitioning to the corporate sector in 2020, I have successfully led R&D strategies, regulatory activities with the EMA, and strategic partnerships, driving innovation from the laboratory to patient-oriented solutions. I hold a PhD in Neuroscience from Miguel Hernández University and have conducted research at world-renowned institutions, including The Scripps Research Institute and UCSF. My scientific contributions include numerous publications in high-impact journals like Science and Neuron. Additionally, I represent Spain on the Management Committee of the pan-European COST Action Retina4Future.

Short Bio: I hold a degree in Biochemistry from the University of Lisbon and a PhD in Health Sciences from the University of Coimbra. Following an academic career in neuroscience research, I transitioned to industry to support the development of innovative therapeutics. Currently, I am Head of Non-clinical Services at VectorB2B, a CRO/CDMO, where I lead preclinical development programs across multiple therapeutic areas and molecule classes. My work spans early discovery through IND-enabling activities, involving strategic planning, project management, and collaboration with academic institutions, biotech and pharmaceutical companies, healthcare professionals, and key opinion leaders. I also supervise a multidisciplinary team delivering non-clinical research and development services.

Short Bio: I am Head of the Department of Nursing and Physiotherapy at Albanian University. I hold a PhD in Pharmaceutical Sciences from the University of Medicine, Tirana, and have a background in both academia and the Albanian healthcare system. My research focuses on precision medicine, oncology, pharmacology, health technology assessment (HTA), artificial intelligence in healthcare, and medical education. I am particularly interested in translating research into clinical practice through interdisciplinary collaboration, data-driven approaches, and innovative healthcare technologies. As a Management Committee member of COST Action CA24105 (Retina4Future), I look forward to contributing my expertise in clinical research methodology, evidence synthesis, and international collaboration to support the development of innovative strategies for retinal disease diagnosis and therapy.